The final analysis contained 407 lung adenocarcinoma patients after the exclusion of 1 patient with osimertinib as first-line treatment, 4 patients with de novo T790M before the first-line EGFR-TKI treatment, 4 patients with adenosquamous cell carcinoma, and 131 patients with more than one EGFR-TKI treatments before re-biopsy. This evidence concerns the gene EGFR and lung adenocarcinoma.